LUPIN2024-10-012024-12-31 LUPIN2024-10-012024-12-31 LUPIN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member LUPIN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member LUPIN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member LUPIN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member LUPIN2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500257 LUPIN NOTLISTED Lupin Limited Equity 2024-04-01 2025-03-31 2025-02-11 2025-01-27 INR Millions Third quarter 21:00:00 23:59:00 2025-02-11 2025-02-11 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Standalone 42080000000.00 553000000.00 42633000000.00 9127800000.00 3312700000.00 -879700000.00 5763700000.00 195500000.00 1525200000.00 10645000000.00 29690200000.00 12942800000.00 -772200000.00 12170600000.00 2257300000.00 66600000.00 2323900000.00 0.00 9846700000.00 0.00 0.00 0.00 0.00 9846700000.00 111900000.00 9958600000.00 0.00 0.00 912500000.00 2 21.58 21.52 0.00 0.00 21.58 21.52 Please note that the Board meeting commenced on February 11, 2025 at 09:00 p.m. (IST) and concluded on February 12, 2025, at 12:10 a.m. (IST). Due to technical issue faced while uploading the XBRL file on NSE Neaps Portal and as suggested by NSE Technical Team, we have mentioned Board Meeting concluded on February 11, 2025, at 23:59 hrs (IST). We request you to consider Board Meeting conclusion date and time as February 12, 2025, at 00:10 hrs (IST). Notes to Financial Results 1. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 11, 2025. The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 2. During the quarter ended December 31, 2024, 91,230 (year-to-date 555,634) equity shares of Rs. 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up share capital by Rs. 0.2 million (year-to-date Rs. 1.1 million) and securities premium account by Rs. 108.3 million (year-to-date Rs. 748.3 million). 3. During the quarter and nine months ended December 31, 2024, the Company has made a provision of Rs. 856.1 million (USD 10 million) towards ongoing dispute. 4. The Company has determined that the carrying value of investment in two wholly owned subsidiaries is higher than the recoverable amount. Accordingly, the Company has provided for impairment in value of investment of Rs. 772.2 million for the quarter and nine months ended December 31, 2024. 5. During the nine months ended December 31, 2024, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9 million (Rs. 750.5 million) in connection with the drug Glumetza® without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. 6. During the nine months ended December 31, 2023 and year ended March 31, 2024, Sales / Income from operations includes milestone income of Rs. 2,052.5 million (USD 25.0 million) from AbbVie for successful achievement of key milestone for its Phase 1 clinical stage MALT1 inhibitor program. 7. During the year ended March 31, 2024, the Company had recognised an impairment charge of Rs. 1,493.9 million related to commercialised intangibles and certain intangibles under development. 8. Pursuant to the meeting of the Board of Directors held on March 22, 2024, the Company has transferred its generic business in India to its wholly owned subsidiary Lupin Life Sciences Limited (formerly known as Lupin Atharva Ability Limited), as a going concern on slump sale basis for a consideration of Rs. 1,100.0 million. 9. Upon execution of the Business Transfer Agreement, the Company on November 01, 2023 had transferred Active Pharmaceutical Ingredients manufacturing sites at Dabhasa and Visakhapatnam and select R&D operations to its wholly owned subsidiary Lupin Manufacturing Solutions Limited, as a going concern on slump sale basis for a consideration of Rs. 7,222.3 million. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 124818300000.00 1252600000.00 126070900000.00 27931200000.00 9691100000.00 -127000000.00 17596500000.00 506500000.00 4397100000.00 32463000000.00 92458400000.00 33612500000.00 -772200000.00 32840300000.00 5868700000.00 155500000.00 6024200000.00 0.00 26816100000.00 0.00 0.00 0.00 0.00 26816100000.00 -28400000.00 26787700000.00 0.00 0.00 912500000.00 2 58.81 58.62 0.00 0.00 58.81 58.62 Net (gain)/loss on foreign currency transactions -554900000.00 Other Expenses 11199900000.00 Net (gain)/loss on foreign currency transactions -776500000.00 Other Expenses 33239500000.00 172000000.00 -43700000.00 60100000.00 -15300000.00 0.00 0.00